Morphosys Reporting
The specialists
After ten years of successful development, MorphoSys launched tafasitamab, its first proprietary compound for the treatment of patients with a specific type of lymphoma – and as a fully integrated biopharmaceutical company is now playing a leading role in a key area of medicine. In our reporting, we accompany the company on this journey, which has one major goal: to cure cancer and autoimmune diseases with antibody-based therapeutics. This is the impact people at MorphoSys work for every day.
The stories impressively focus on the commitment of people for people.
The characteristic brand colors and the strong graphic language form the design focal point with recognition value. Digital and in print.
Questions about the project?
Isabel Rode
